drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00810 | DB01246 | 456 | 820 | [
"DDInter211",
"DDInter45"
] | Biperiden | Alimemazine | A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
456,
24,
820
]
],
[
[
456,
24,
104
],
[
104,
40,
820
]
],
[
[
456,
24,
401
],
[
401,
24,
820
]
],
[
[
456,
24,
649
],
[
649,
1,
... | [
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
... | Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction tha... |
DB04844 | DB14568 | 843 | 982 | [
"DDInter1778",
"DDInter1000"
] | Tetrabenazine | Ivosidenib | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
843,
25,
982
]
],
[
[
843,
62,
112
],
[
112,
23,
982
]
],
[
[
843,
63,
543
],
[
543,
24,
982
]
],
[
[
843,
24,
28
],
[
28,
24,
... | [
[
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Tetrabenazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Tetrabenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide an... |
DB00574 | DB01064 | 121 | 1,148 | [
"DDInter717",
"DDInter987"
] | Fenfluramine | Isoprenaline | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
121,
24,
1148
]
],
[
[
121,
24,
480
],
[
480,
24,
1148
]
],
[
[
121,
24,
1354
],
[
1354,
63,
1148
]
],
[
[
121,
64,
534
],
[
534,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa and D... |
DB00501 | DB11828 | 752 | 1,406 | [
"DDInter380",
"DDInter1281"
] | Cimetidine | Neratinib | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Major | 2 | [
[
[
752,
25,
1406
]
],
[
[
752,
23,
1135
],
[
1135,
23,
1406
]
],
[
[
752,
24,
392
],
[
392,
24,
1406
]
],
[
[
752,
62,
1252
],
[
1252,
... | [
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may ... |
DB00501 | DB12941 | 752 | 466 | [
"DDInter380",
"DDInter481"
] | Cimetidine | Darolutamide | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Minor | 0 | [
[
[
752,
23,
466
]
],
[
[
752,
23,
1622
],
[
1622,
23,
466
]
],
[
[
752,
24,
34
],
[
34,
23,
466
]
],
[
[
752,
24,
159
],
[
159,
62,... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Voriconazole"
],
[
... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Voriconazole and Voriconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and F... |
DB00030 | DB00263 | 1,685 | 1,029 | [
"DDInter934",
"DDInter1727"
] | Insulin human | Sulfisoxazole | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. | Moderate | 1 | [
[
[
1685,
24,
1029
]
],
[
[
1685,
24,
1247
],
[
1247,
40,
1029
]
],
[
[
1685,
24,
161
],
[
161,
1,
1029
]
],
[
[
1685,
24,
245
],
[
245,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfisoxazole"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfisoxazole (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound) resembl... |
DB00434 | DB00810 | 13 | 456 | [
"DDInter459",
"DDInter211"
] | Cyproheptadine | Biperiden | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine. | Moderate | 1 | [
[
[
13,
24,
456
]
],
[
[
13,
63,
1105
],
[
1105,
40,
456
]
],
[
[
13,
6,
4304
],
[
4304,
45,
456
]
],
[
[
13,
7,
1898
],
[
1898,
46,... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Biperiden"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trihexyphenidyl"
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Trihexyphenidyl and Trihexyphenidyl (Compound) resembles Biperiden (Compound)
Cyproheptadine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Biperiden (Compound)
Cyproheptadine (Compound) upregulates GADD45A (Gene)... |
DB00361 | DB05679 | 134 | 1,683 | [
"DDInter1939",
"DDInter1907"
] | Vinorelbine | Ustekinumab | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
134,
24,
1683
]
],
[
[
134,
63,
1461
],
[
1461,
23,
1683
]
],
[
[
134,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
134,
24,
1001
],
[
1001,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib ... |
DB00352 | DB08903 | 482 | 996 | [
"DDInter1814",
"DDInter170"
] | Tioguanine | Bedaquiline | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
482,
24,
996
]
],
[
[
482,
21,
28722
],
[
28722,
60,
996
]
],
[
[
482,
24,
713
],
[
713,
63,
996
]
],
[
[
482,
24,
848
],
[
848,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by... | Tioguanine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Bedaquiline (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00501 | DB01124 | 752 | 1,411 | [
"DDInter380",
"DDInter1828"
] | Cimetidine | Tolbutamide | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
752,
24,
1411
]
],
[
[
752,
24,
959
],
[
959,
40,
1411
]
],
[
[
752,
63,
245
],
[
245,
40,
1411
]
],
[
[
752,
6,
10215
],
[
10215,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound... |
DB00405 | DB00909 | 128 | 306 | [
"DDInter517",
"DDInter1971"
] | Dexbrompheniramine | Zonisamide | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Major | 2 | [
[
[
128,
25,
306
]
],
[
[
128,
24,
1609
],
[
1609,
63,
306
]
],
[
[
128,
24,
717
],
[
717,
24,
306
]
],
[
[
128,
63,
475
],
[
475,
2... | [
[
[
"Dexbrompheniramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
],
... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Zonisamide
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00087 | DB01041 | 599 | 770 | [
"DDInter41",
"DDInter1789"
] | Alemtuzumab | Thalidomide | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
599,
24,
770
]
],
[
[
599,
24,
1668
],
[
1668,
1,
770
]
],
[
[
599,
24,
4
],
[
4,
63,
770
]
],
[
[
599,
24,
1401
],
[
1401,
24,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Thalidomide (Compound)
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may ca... |
DB00063 | DB00278 | 366 | 291 | [
"DDInter659",
"DDInter117"
] | Eptifibatide | Argatroban | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Major | 2 | [
[
[
366,
25,
291
]
],
[
[
366,
23,
297
],
[
297,
62,
291
]
],
[
[
366,
24,
972
],
[
972,
63,
291
]
],
[
[
366,
24,
1230
],
[
1230,
2... | [
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Argatroban"
]
],
[
[
"Eptifibatide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
... | Eptifibatide may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Argatroban
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Choline ... |
DB00745 | DB09143 | 307 | 313 | [
"DDInter1236",
"DDInter1701"
] | Modafinil | Sonidegib | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
307,
25,
313
]
],
[
[
307,
63,
837
],
[
837,
23,
313
]
],
[
[
307,
24,
379
],
[
379,
23,
313
]
],
[
[
307,
23,
478
],
[
478,
24,... | [
[
[
"Modafinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazol... | Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabepr... |
DB00197 | DB08880 | 1,324 | 1,510 | [
"DDInter1881",
"DDInter1771"
] | Troglitazone | Teriflunomide | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1324,
25,
1510
]
],
[
[
1324,
23,
608
],
[
608,
23,
1510
]
],
[
[
1324,
24,
129
],
[
129,
63,
1510
]
],
[
[
1324,
23,
1612
],
[
1612,
... | [
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidoca... | Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enz... |
DB00451 | DB00598 | 542 | 1,523 | [
"DDInter1064",
"DDInter1013"
] | Levothyroxine | Labetalol | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Minor | 0 | [
[
[
542,
23,
1523
]
],
[
[
542,
24,
532
],
[
532,
1,
1523
]
],
[
[
542,
21,
28936
],
[
28936,
60,
1523
]
],
[
[
542,
40,
1152
],
[
1152,
... | [
[
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Labetalol"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
],
[... | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine (Compound) resembles Labetalol (Compound)
Levothyroxine (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Labetalol (Compound)
Levothyroxine (Compound) resembl... |
DB00630 | DB11126 | 1,485 | 900 | [
"DDInter42",
"DDInter276"
] | Alendronic acid | Calcium gluconate | Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injecti... | Moderate | 1 | [
[
[
1485,
24,
900
]
],
[
[
1485,
1,
1199
],
[
1199,
24,
900
]
],
[
[
1485,
1,
1199
],
[
1199,
1,
1008
],
[
1008,
24,
900
]
],
[
[
1485,
... | [
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Alendronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Ibandronate"
],
[
"Ibandronate",
"{u} ... | Alendronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Alendronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate (Compound) resembles Risedronic acid (Compound) and Risedronic acid ma... |
DB00281 | DB04861 | 608 | 1,592 | [
"DDInter1066",
"DDInter1271"
] | Lidocaine | Nebivolol | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
608,
24,
1592
]
],
[
[
608,
6,
12523
],
[
12523,
45,
1592
]
],
[
[
608,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
608,
24,
1419
],
[
141... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Lidocaine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Nebivolol (Compound)
Lidocaine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may ... |
DB00372 | DB00460 | 999 | 612 | [
"DDInter1793",
"DDInter1929"
] | Thiethylperazine | Verteporfin | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Moderate | 1 | [
[
[
999,
24,
612
]
],
[
[
999,
24,
959
],
[
959,
63,
612
]
],
[
[
999,
63,
1214
],
[
1214,
24,
612
]
],
[
[
999,
24,
959
],
[
959,
2... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verteporfin"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Verteporfin
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Minoxidil ... |
DB00398 | DB00539 | 79 | 11 | [
"DDInter1702",
"DDInter1837"
] | Sorafenib | Toremifene | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Major | 2 | [
[
[
79,
25,
11
]
],
[
[
79,
6,
4973
],
[
4973,
45,
11
]
],
[
[
79,
7,
16941
],
[
16941,
46,
11
]
],
[
[
79,
18,
6134
],
[
6134,
46,
... | [
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Toremifene"... | Sorafenib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Toremifene (Compound)
Sorafenib (Compound) upregulates MICALL1 (Gene) and MICALL1 (Gene) is upregulated by Toremifene (Compound)
Sorafenib (Compound) downregulates SQLE (Gene) and SQLE (Gene) is upregulated by Toremifene (Compound)
Sorafenib (Compound... |
DB00006 | DB06228 | 942 | 792 | [
"DDInter217",
"DDInter1609"
] | Bivalirudin | Rivaroxaban | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Major | 2 | [
[
[
942,
25,
792
]
],
[
[
942,
23,
944
],
[
944,
62,
792
]
],
[
[
942,
24,
901
],
[
901,
24,
792
]
],
[
[
942,
24,
738
],
[
738,
63,... | [
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Bivalirudin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile"... | Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Rivaroxaban
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacip... |
DB01015 | DB08912 | 1,247 | 1,040 | [
"DDInter1724",
"DDInter462"
] | Sulfamethoxazole | Dabrafenib | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1247,
24,
1040
]
],
[
[
1247,
6,
3486
],
[
3486,
45,
1040
]
],
[
[
1247,
7,
9900
],
[
9900,
46,
1040
]
],
[
[
1247,
18,
1918
],
[
1918... | [
[
[
"Sulfamethoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Sulfamethoxazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} ... | Sulfamethoxazole (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dabrafenib (Compound)
Sulfamethoxazole (Compound) upregulates SLC1A4 (Gene) and SLC1A4 (Gene) is upregulated by Dabrafenib (Compound)
Sulfamethoxazole (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Dabrafenib (Compou... |
DB00938 | DB09054 | 455 | 384 | [
"DDInter1635",
"DDInter905"
] | Salmeterol | Idelalisib | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
455,
25,
384
]
],
[
[
455,
24,
222
],
[
222,
23,
384
]
],
[
[
455,
63,
1230
],
[
1230,
23,
384
]
],
[
[
455,
24,
1618
],
[
1618,
... | [
[
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutrami... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalo... |
DB00059 | DB01128 | 1,560 | 918 | [
"DDInter1404",
"DDInter204"
] | Pegaspargase | Bicalutamide | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Moderate | 1 | [
[
[
1560,
24,
918
]
],
[
[
1560,
24,
1247
],
[
1247,
23,
918
]
],
[
[
1560,
24,
786
],
[
786,
63,
918
]
],
[
[
1560,
24,
473
],
[
473,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Bicalutamide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Rilpi... |
DB00250 | DB09570 | 10 | 1,480 | [
"DDInter475",
"DDInter1002"
] | Dapsone | Ixazomib | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
10,
24,
1480
]
],
[
[
10,
63,
268
],
[
268,
24,
1480
]
],
[
[
10,
24,
148
],
[
148,
63,
1480
]
],
[
[
10,
24,
453
],
[
453,
24,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
[... | Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Secnida... |
DB01067 | DB09154 | 959 | 1,475 | [
"DDInter826",
"DDInter1686"
] | Glipizide | Sodium citrate | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Minor | 0 | [
[
[
959,
23,
1475
]
],
[
[
959,
24,
1603
],
[
1603,
23,
1475
]
],
[
[
959,
63,
610
],
[
610,
23,
1475
]
],
[
[
959,
40,
1411
],
[
1411,
... | [
[
[
"Glipizide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
],
[
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril... |
DB00539 | DB04844 | 11 | 843 | [
"DDInter1837",
"DDInter1778"
] | Toremifene | Tetrabenazine | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Major | 2 | [
[
[
11,
25,
843
]
],
[
[
11,
24,
479
],
[
479,
40,
843
]
],
[
[
11,
7,
10439
],
[
10439,
46,
843
]
],
[
[
11,
7,
15786
],
[
15786,
5... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezi... | Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Toremifene (Compound) upregulates PROS1 (Gene) and PROS1 (Gene) is upregulated by Tetrabenazine (Compound)
Toremifene (Compound) upregulates TCTN1 (Gene) and T... |
DB00026 | DB00682 | 1,184 | 126 | [
"DDInter94",
"DDInter1951"
] | Anakinra | Warfarin | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
1184,
24,
126
]
],
[
[
1184,
24,
362
],
[
362,
24,
126
]
],
[
[
1184,
24,
168
],
[
168,
23,
126
]
],
[
[
1184,
24,
1001
],
[
1001,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Ph... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may... |
DB01105 | DB15093 | 222 | 1,654 | [
"DDInter1665",
"DDInter1698"
] | Sibutramine | Somapacitan | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
222,
24,
1654
]
],
[
[
222,
24,
433
],
[
433,
24,
1654
]
],
[
[
222,
63,
176
],
[
176,
24,
1654
]
],
[
[
222,
23,
351
],
[
351,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glar... |
DB00734 | DB05294 | 1,664 | 1,069 | [
"DDInter1605",
"DDInter1917"
] | Risperidone | Vandetanib | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
1664,
25,
1069
]
],
[
[
1664,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
1664,
21,
28719
],
[
28719,
60,
1069
]
],
[
[
1664,
23,
1194
],
[
1... | [
[
[
"Risperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Risperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vande... | Risperidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Risperidone (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Vandetanib (Compound)
Risperidone may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine ma... |
DB01169 | DB01344 | 57 | 1,231 | [
"DDInter120",
"DDInter1830"
] | Arsenic trioxide | Tolevamer | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Major | 2 | [
[
[
57,
25,
1231
]
],
[
[
57,
25,
519
],
[
519,
24,
1231
]
],
[
[
57,
64,
1178
],
[
1178,
24,
1231
]
],
[
[
57,
25,
924
],
[
924,
63... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paliperidone"
],
[
"Paliperidone... | Arsenic trioxide may lead to a major life threatening interaction when taken with Paliperidone and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Arsenic trioxide may lead to a major life threatening interaction when taken with Trifluoperazine and Trifluoperazine ... |
DB00662 | DB01219 | 717 | 716 | [
"DDInter1873",
"DDInter473"
] | Trimethobenzamide | Dantrolene | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Moderate | 1 | [
[
[
717,
24,
716
]
],
[
[
717,
21,
28751
],
[
28751,
60,
716
]
],
[
[
717,
24,
1609
],
[
1609,
63,
716
]
],
[
[
717,
24,
100
],
[
100,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Trimethobenzamide",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side... | Trimethobenzamide (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Dantrolene (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases w... |
DB00404 | DB09104 | 523 | 286 | [
"DDInter54",
"DDInter1118"
] | Alprazolam | Magnesium hydroxide | Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down ... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Minor | 0 | [
[
[
523,
23,
286
]
],
[
[
523,
1,
481
],
[
481,
23,
286
]
],
[
[
523,
24,
820
],
[
820,
23,
286
]
],
[
[
523,
40,
1119
],
[
1119,
23... | [
[
[
"Alprazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Alprazolam",
"{u} (Compound) resembles {v} (Compound)",
"Quazepam"
],
[
"Quazepam",
"{u} may cause a mino... | Alprazolam (Compound) resembles Quazepam (Compound) and Quazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can... |
DB06589 | DB08864 | 1,250 | 786 | [
"DDInter1400",
"DDInter1595"
] | Pazopanib | Rilpivirine | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
1250,
35,
786
]
],
[
[
1250,
63,
655
],
[
655,
1,
786
]
],
[
[
1250,
6,
8374
],
[
8374,
45,
786
]
],
[
[
1250,
21,
29343
],
[
29343,
... | [
[
[
"Pazopanib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken wi... | Pazopanib (Compound) resembles Rilpivirine (Compound) and
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Pazopanib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Pazopani... |
DB00261 | DB11796 | 702 | 1,612 | [
"DDInter93",
"DDInter786"
] | Anagrelide | Fostemsavir | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Major | 2 | [
[
[
702,
25,
1612
]
],
[
[
702,
23,
112
],
[
112,
23,
1612
]
],
[
[
702,
25,
1424
],
[
1424,
24,
1612
]
],
[
[
702,
25,
823
],
[
823,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Anagrelide may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a m... |
DB01157 | DB09061 | 304 | 1,627 | [
"DDInter1875",
"DDInter284"
] | Trimetrexate | Cannabidiol | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
304,
24,
1627
]
],
[
[
304,
62,
600
],
[
600,
23,
1627
]
],
[
[
304,
24,
384
],
[
384,
23,
1627
]
],
[
[
304,
63,
597
],
[
597,
... | [
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Trimetrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
... | Trimetrexate may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Ide... |
DB09241 | DB11632 | 1,629 | 580 | [
"DDInter1186",
"DDInter1343"
] | Methylene blue | Opicapone | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) in... | Major | 2 | [
[
[
1629,
25,
580
]
],
[
[
1629,
64,
475
],
[
475,
24,
580
]
],
[
[
1629,
63,
1311
],
[
1311,
24,
580
]
],
[
[
1629,
25,
407
],
[
407,
... | [
[
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opicapone"
]
],
[
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u... | Methylene blue may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide... |
DB01320 | DB09038 | 651 | 1,450 | [
"DDInter783",
"DDInter636"
] | Fosphenytoin | Empagliflozin | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
651,
24,
1450
]
],
[
[
651,
63,
1486
],
[
1486,
24,
1450
]
],
[
[
651,
25,
1017
],
[
1017,
63,
1450
]
],
[
[
651,
25,
1510
],
[
1510,
... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
... | Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Fosphenytoin may lead to a major life threatening interaction when taken with Lorlatinib an... |
DB01088 | DB04896 | 714 | 901 | [
"DDInter908",
"DDInter1220"
] | Iloprost | Milnacipran | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Moderate | 1 | [
[
[
714,
24,
901
]
],
[
[
714,
24,
41
],
[
41,
1,
901
]
],
[
[
714,
25,
405
],
[
405,
63,
901
]
],
[
[
714,
24,
256
],
[
256,
63,
... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Iloprost may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could e... |
DB00193 | DB00486 | 534 | 1,614 | [
"DDInter1841",
"DDInter1253"
] | Tramadol | Nabilone | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
534,
24,
1614
]
],
[
[
534,
25,
530
],
[
530,
1,
1614
]
],
[
[
534,
21,
28789
],
[
28789,
60,
1614
]
],
[
[
534,
25,
999
],
[
999,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
... | Tramadol may lead to a major life threatening interaction when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Tramadol (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Nabilone (Compound)
Tramadol may lead to a major life threateni... |
DB00877 | DB11986 | 629 | 484 | [
"DDInter1678",
"DDInter648"
] | Sirolimus | Entrectinib | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
629,
24,
484
]
],
[
[
629,
24,
222
],
[
222,
23,
484
]
],
[
[
629,
23,
907
],
[
907,
62,
484
]
],
[
[
629,
63,
1197
],
[
1197,
2... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirin... |
DB06626 | DB08881 | 263 | 868 | [
"DDInter147",
"DDInter1925"
] | Axitinib | Vemurafenib | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
263,
24,
868
]
],
[
[
263,
63,
122
],
[
122,
23,
868
]
],
[
[
263,
24,
578
],
[
578,
24,
868
]
],
[
[
263,
25,
760
],
[
760,
63,... | [
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
],
[
... | Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor ma... |
DB01244 | DB06595 | 762 | 1,491 | [
"DDInter192",
"DDInter1214"
] | Bepridil | Midostaurin | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
762,
25,
1491
]
],
[
[
762,
23,
1135
],
[
1135,
62,
1491
]
],
[
[
762,
62,
112
],
[
112,
23,
1491
]
],
[
[
762,
64,
888
],
[
888,
... | [
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Bepridil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Bepridil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Bepridil may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole ... |
DB00095 | DB15719 | 66 | 487 | [
"DDInter623",
"DDInter171"
] | Efalizumab | Belantamab mafodotin | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF). Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma; however, its manufa... | Moderate | 1 | [
[
[
66,
24,
487
]
],
[
[
66,
24,
259
],
[
259,
24,
487
]
],
[
[
66,
63,
1184
],
[
1184,
24,
487
]
],
[
[
66,
25,
976
],
[
976,
25,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belantamab mafodotin"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Belantamab mafodotin
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra an... |
DB01032 | DB08826 | 824 | 1,292 | [
"DDInter1522",
"DDInter489"
] | Probenecid | Deferiprone | The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Moderate | 1 | [
[
[
824,
24,
1292
]
],
[
[
824,
18,
7242
],
[
7242,
57,
1292
]
],
[
[
824,
21,
28762
],
[
28762,
60,
1292
]
],
[
[
824,
62,
1512
],
[
1512... | [
[
[
"Probenecid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deferiprone"
]
],
[
[
"Probenecid",
"{u} (Compound) downregulates {v} (Gene)",
"PHKA1"
],
[
"PHKA1",
"{u} (Gene) is downregulated by {... | Probenecid (Compound) downregulates PHKA1 (Gene) and PHKA1 (Gene) is downregulated by Deferiprone (Compound)
Probenecid (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Deferiprone (Compound)
Probenecid may cause a minor interaction that can limit clinical effects when taken with Diclofe... |
DB06655 | DB06788 | 5 | 1,616 | [
"DDInter1077",
"DDInter864"
] | Liraglutide | Histrelin | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
5,
24,
1616
]
],
[
[
5,
63,
1664
],
[
1664,
24,
1616
]
],
[
[
5,
24,
1296
],
[
1296,
63,
1616
]
],
[
[
5,
63,
684
],
[
684,
25,
... | [
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec a... |
DB06016 | DB11979 | 1,508 | 1,320 | [
"DDInter300",
"DDInter625"
] | Cariprazine | Elagolix | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1508,
24,
1320
]
],
[
[
1508,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
1508,
24,
484
],
[
484,
63,
1320
]
],
[
[
1508,
63,
597
],
[
597,
... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and E... |
DB08912 | DB09154 | 1,040 | 1,475 | [
"DDInter462",
"DDInter1686"
] | Dabrafenib | Sodium citrate | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
1040,
24,
1475
]
],
[
[
1040,
64,
263
],
[
263,
23,
1475
]
],
[
[
1040,
63,
902
],
[
902,
23,
1475
]
],
[
[
1040,
25,
1406
],
[
1406,
... | [
[
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Dabrafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
],
[
"Axitinib... | Dabrafenib may lead to a major life threatening interaction when taken with Axitinib and Axitinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam may cause a mino... |
DB00712 | DB01082 | 1,274 | 1,448 | [
"DDInter763",
"DDInter1713"
] | Flurbiprofen | Streptomycin | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Moderate | 1 | [
[
[
1274,
24,
1448
]
],
[
[
1274,
6,
10612
],
[
10612,
45,
1448
]
],
[
[
1274,
21,
29327
],
[
29327,
60,
1448
]
],
[
[
1274,
24,
1332
],
[
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Com... | Flurbiprofen (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Streptomycin (Compound)
Flurbiprofen (Compound) causes Renal failure (Side Effect) and Renal failure (Side Effect) is caused by Streptomycin (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00358 | DB11932 | 1,010 | 327 | [
"DDInter1140",
"DDInter3"
] | Mefloquine | Abametapir (topical) | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
1010,
24,
327
]
],
[
[
1010,
24,
124
],
[
124,
63,
327
]
],
[
[
1010,
24,
79
],
[
79,
24,
327
]
],
[
[
1010,
25,
1069
],
[
1069,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Mefloquine m... |
DB09074 | DB09280 | 1,362 | 1,604 | [
"DDInter1327",
"DDInter1101"
] | Olaparib | Lumacaftor | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
1362,
25,
1604
]
],
[
[
1362,
24,
1060
],
[
1060,
62,
1604
]
],
[
[
1362,
63,
628
],
[
628,
24,
1604
]
],
[
[
1362,
64,
307
],
[
307,
... | [
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfort... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ergometrine... |
DB00398 | DB01611 | 79 | 1,487 | [
"DDInter1702",
"DDInter893"
] | Sorafenib | Hydroxychloroquine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Major | 2 | [
[
[
79,
25,
1487
]
],
[
[
79,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
79,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
79,
21,
28658
],
[
28658,
... | [
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"Prim... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Sorafenib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Sorafenib (Compound... |
DB00099 | DB01101 | 440 | 60 | [
"DDInter735",
"DDInter285"
] | Filgrastim | Capecitabine | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
440,
24,
60
]
],
[
[
440,
24,
309
],
[
309,
62,
60
]
],
[
[
440,
24,
147
],
[
147,
23,
60
]
],
[
[
440,
63,
599
],
[
599,
24,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vin... |
DB06043 | DB14409 | 1,644 | 1,129 | [
"DDInter1328",
"DDInter867"
] | Olaratumab | Human adenovirus e serotype 4 strain cl-68578 antigen | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Stu... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1644,
24,
1129
]
],
[
[
1644,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1644,
63,
1683
],
[
1683,
24,
1129
]
],
[
[
1644,
25,
1259
],
[
12... | [
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Olaratumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Olaratumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Olaratumab may cause a moderate interaction that could exacerbate diseases when take... |
DB00694 | DB10989 | 51 | 496 | [
"DDInter485",
"DDInter858"
] | Daunorubicin | Hepatitis A Vaccine | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
51,
24,
496
]
],
[
[
51,
24,
4
],
[
4,
24,
496
]
],
[
[
51,
63,
147
],
[
147,
24,
496
]
],
[
[
51,
24,
738
],
[
738,
63,
4... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine me... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Daunorubicin may cause a moderate interaction that could exacerbate dis... |
DB01069 | DB01278 | 401 | 1,021 | [
"DDInter1533",
"DDInter1506"
] | Promethazine | Pramlintide | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
401,
24,
1021
]
],
[
[
401,
63,
1680
],
[
1680,
24,
1021
]
],
[
[
401,
64,
839
],
[
839,
24,
1021
]
],
[
[
401,
24,
1539
],
[
1539,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
],... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Promethazine may lead to a major life threatening interaction when taken with Grepafloxacin and Grepa... |
DB00741 | DB01320 | 167 | 651 | [
"DDInter885",
"DDInter783"
] | Hydrocortisone | Fosphenytoin | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
167,
24,
651
]
],
[
[
167,
23,
307
],
[
307,
1,
651
]
],
[
[
167,
63,
362
],
[
362,
1,
651
]
],
[
[
167,
24,
998
],
[
998,
1,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
... | Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Fosphenytoin (Compound)
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Comp... |
DB00544 | DB00999 | 970 | 504 | [
"DDInter757",
"DDInter883"
] | Fluorouracil | Hydrochlorothiazide | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Moderate | 1 | [
[
[
970,
24,
504
]
],
[
[
970,
24,
178
],
[
178,
1,
504
]
],
[
[
970,
63,
323
],
[
323,
40,
504
]
],
[
[
970,
24,
359
],
[
359,
40,
... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide (Compoun... |
DB00912 | DB01138 | 473 | 804 | [
"DDInter1581",
"DDInter1726"
] | Repaglinide | Sulfinpyrazone | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Moderate | 1 | [
[
[
473,
24,
804
]
],
[
[
473,
63,
998
],
[
998,
1,
804
]
],
[
[
473,
6,
3486
],
[
3486,
45,
804
]
],
[
[
473,
63,
168
],
[
168,
23,... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfinpyrazone"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"
]... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Sulfinpyrazone (Compound)
Repaglinide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sulfinpyrazone (Compound)
Repaglinide may cause a moderate interaction tha... |
DB05679 | DB10316 | 1,683 | 334 | [
"DDInter1907",
"DDInter1248"
] | Ustekinumab | Mumps virus strain B level jeryl lynn live antigen | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
1683,
25,
334
]
],
[
[
1683,
63,
1042
],
[
1042,
24,
334
]
],
[
[
1683,
24,
594
],
[
594,
25,
334
]
],
[
[
1683,
64,
1057
],
[
1057,
... | [
[
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Ustekinumab may cause a moderate interaction that could exacerb... |
DB00055 | DB04896 | 834 | 901 | [
"DDInter605",
"DDInter1220"
] | Drotrecogin alfa | Milnacipran | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Moderate | 1 | [
[
[
834,
24,
901
]
],
[
[
834,
24,
41
],
[
41,
1,
901
]
],
[
[
834,
25,
405
],
[
405,
63,
901
]
],
[
[
834,
25,
500
],
[
500,
24,
... | [
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipra... | Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interact... |
DB00877 | DB06589 | 629 | 1,250 | [
"DDInter1678",
"DDInter1400"
] | Sirolimus | Pazopanib | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
629,
24,
1250
]
],
[
[
629,
7,
10365
],
[
10365,
45,
1250
]
],
[
[
629,
6,
15333
],
[
15333,
45,
1250
]
],
[
[
629,
7,
3553
],
[
3553,... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Sirolimus",
"{u} (Compound) upregulates {v} (Gene)",
"STK10"
],
[
"STK10",
"{u} (Gene) is bound by {v} (Compound)"... | Sirolimus (Compound) upregulates STK10 (Gene) and STK10 (Gene) is bound by Pazopanib (Compound)
Sirolimus (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Pazopanib (Compound)
Sirolimus (Compound) upregulates CRIP1 (Gene) and CRIP1 (Gene) is upregulated by Pazopanib (Compound)
Sirolimus (Compound) downreg... |
DB00881 | DB09154 | 954 | 1,475 | [
"DDInter1554",
"DDInter1686"
] | Quinapril | Sodium citrate | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Minor | 0 | [
[
[
954,
23,
1475
]
],
[
[
954,
40,
610
],
[
610,
23,
1475
]
],
[
[
954,
24,
1411
],
[
1411,
23,
1475
]
],
[
[
954,
63,
590
],
[
590,
... | [
[
[
"Quinapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
]
],
[
[
"Quinapril",
"{u} (Compound) resembles {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} may cause a minor int... | Quinapril (Compound) resembles Enalapril (Compound) and Enalapril may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limi... |
DB00363 | DB08904 | 695 | 375 | [
"DDInter419",
"DDInter342"
] | Clozapine | Certolizumab pegol | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
695,
25,
375
]
],
[
[
695,
25,
1593
],
[
1593,
24,
375
]
],
[
[
695,
64,
10
],
[
10,
24,
375
]
],
[
[
695,
24,
303
],
[
303,
24,... | [
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
... | Clozapine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Clozapine may lead to a major life threatening interaction when taken with Dapsone and Dapsone may cause a moderate inte... |
DB01240 | DB06209 | 885 | 256 | [
"DDInter657",
"DDInter1508"
] | Epoprostenol | Prasugrel | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Moderate | 1 | [
[
[
885,
24,
256
]
],
[
[
885,
6,
17955
],
[
17955,
45,
256
]
],
[
[
885,
21,
28681
],
[
28681,
60,
256
]
],
[
[
885,
23,
944
],
[
944,
... | [
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Epoprostenol",
"{u} (Compound) binds {v} (Gene)",
"P2RY12"
],
[
"P2RY12",
"{u} (Gene) is bound by {v} (Compound... | Epoprostenol (Compound) binds P2RY12 (Gene) and P2RY12 (Gene) is bound by Prasugrel (Compound)
Epoprostenol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Cha... |
DB00836 | DB08903 | 543 | 996 | [
"DDInter1088",
"DDInter170"
] | Loperamide | Bedaquiline | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
543,
24,
996
]
],
[
[
543,
40,
649
],
[
649,
1,
996
]
],
[
[
543,
24,
1376
],
[
1376,
1,
996
]
],
[
[
543,
24,
358
],
[
358,
40,... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Loperamide",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembl... | Loperamide (Compound) resembles Clofedanol (Compound) and Clofedanol (Compound) resembles Bedaquiline (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Bedaquiline (Compound)
Loperamide may cause a moderate inte... |
DB00364 | DB01136 | 417 | 772 | [
"DDInter1717",
"DDInter305"
] | Sucralfate | Carvedilol | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Minor | 0 | [
[
[
417,
23,
772
]
],
[
[
417,
21,
30077
],
[
30077,
60,
772
]
],
[
[
417,
23,
542
],
[
542,
23,
772
]
],
[
[
417,
62,
1152
],
[
1152,
... | [
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Carvedilol"
]
],
[
[
"Sucralfate",
"{u} (Compound) causes {v} (Side Effect)",
"Fluid overload"
],
[
"Fluid overload",
"{u} (Side Effect)... | Sucralfate (Compound) causes Fluid overload (Side Effect) and Fluid overload (Side Effect) is caused by Carvedilol (Compound)
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Levothyroxine and Levothyroxine may cause a minor interaction that can limit clinical effects when taken ... |
DB01592 | DB06723 | 1,596 | 115 | [
"DDInter975",
"DDInter58"
] | Iron | Aluminum hydroxide | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletio... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
1596,
24,
115
]
],
[
[
1596,
21,
28872
],
[
28872,
60,
115
]
],
[
[
1596,
63,
1191
],
[
1191,
23,
115
]
],
[
[
1596,
62,
752
],
[
752,... | [
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Iron",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
"{u} (Side Effect) is ... | Iron (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Aluminum hydroxide (Compound)
Iron may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa may cause a minor interaction that can limit clinical effects when taken with Aluminum ... |
DB00775 | DB06754 | 1,226 | 707 | [
"DDInter1818",
"DDInter471"
] | Tirofiban | Danaparoid | Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Major | 2 | [
[
[
1226,
25,
707
]
],
[
[
1226,
23,
944
],
[
944,
62,
707
]
],
[
[
1226,
24,
1496
],
[
1496,
63,
707
]
],
[
[
1226,
24,
901
],
[
901,
... | [
[
[
"Tirofiban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Tirofiban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Tirofiban may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Danaparoid
Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may... |
DB06273 | DB08908 | 980 | 713 | [
"DDInter1824",
"DDInter564"
] | Tocilizumab | Dimethyl fumarate | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
980,
24,
713
]
],
[
[
980,
24,
996
],
[
996,
24,
713
]
],
[
[
980,
63,
4
],
[
4,
24,
713
]
],
[
[
980,
64,
1394
],
[
1394,
24,
... | [
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]... | Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxin... |
DB09420 | DB11119 | 1,074 | 120 | [
"DDInter953",
"DDInter1689"
] | Iodide I-123 | Sodium iodide | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Sodium iodide is a water-soluble ionic compound with a crystal lattice. Sodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition but is more commonly used in veterinary medicine. Radiolabelled compound, , is used as a diagnostic tool to evaluate thyroid function and mor... | Moderate | 1 | [
[
[
1074,
24,
120
]
],
[
[
1074,
63,
1486
],
[
1486,
24,
116
],
[
116,
24,
120
]
],
[
[
1074,
24,
1434
],
[
1434,
63,
116
],
[
116,
24,
... | [
[
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium iodide"
]
],
[
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
... | Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00342 | DB00346 | 1,181 | 472 | [
"DDInter1770",
"DDInter44"
] | Terfenadine | Alfuzosin | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Moderate | 1 | [
[
[
1181,
24,
472
]
],
[
[
1181,
25,
752
],
[
752,
62,
472
]
],
[
[
1181,
23,
112
],
[
112,
62,
472
]
],
[
[
1181,
24,
1151
],
[
1151,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfuzosin"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cimetidine"
],
[
"Cimetidin... | Terfenadine may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Alfuzosin
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cau... |
DB00242 | DB09122 | 1,064 | 1,613 | [
"DDInter392",
"DDInter1409"
] | Cladribine | Peginterferon beta-1a | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1064,
24,
1613
]
],
[
[
1064,
25,
975
],
[
975,
63,
1613
]
],
[
[
1064,
64,
168
],
[
168,
24,
1613
]
],
[
[
1064,
25,
208
],
[
208,
... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
],
[
... | Cladribine may lead to a major life threatening interaction when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Cladribine may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may caus... |
DB00902 | DB00924 | 104 | 1,405 | [
"DDInter1168",
"DDInter454"
] | Methdilazine | Cyclobenzaprine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184... | Moderate | 1 | [
[
[
104,
24,
1405
]
],
[
[
104,
1,
293
],
[
293,
1,
1405
]
],
[
[
104,
63,
1302
],
[
1302,
1,
1405
]
],
[
[
104,
24,
358
],
[
358,
1... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
]
],
[
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Imipramine"
],
[
"Imipramine",
"{u} (Compound)... | Methdilazine (Compound) resembles Imipramine (Compound) and Imipramine (Compound) resembles Cyclobenzaprine (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Cyclobenzaprine (Compound)
Methdilazine may cause a mod... |
DB00836 | DB01268 | 543 | 1,151 | [
"DDInter1088",
"DDInter1731"
] | Loperamide | Sunitinib | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
543,
24,
1151
]
],
[
[
543,
6,
4973
],
[
4973,
45,
1151
]
],
[
[
543,
7,
9650
],
[
9650,
46,
1151
]
],
[
[
543,
18,
6317
],
[
6317,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Loperamide",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Loperamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sunitinib (Compound)
Loperamide (Compound) upregulates HMGCS1 (Gene) and HMGCS1 (Gene) is upregulated by Sunitinib (Compound)
Loperamide (Compound) downregulates MRPL12 (Gene) and MRPL12 (Gene) is downregulated by Sunitinib (Compound)
Loperamide (Com... |
DB06288 | DB09268 | 607 | 1,662 | [
"DDInter77",
"DDInter1464"
] | Amisulpride | Picosulfuric acid | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
607,
24,
1662
]
],
[
[
607,
25,
484
],
[
484,
63,
1662
]
],
[
[
607,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
607,
64,
1342
],
[
1342,
... | [
[
[
"Amisulpride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"... | Amisulpride may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Amisulpride may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause ... |
DB00927 | DB06788 | 1,559 | 1,616 | [
"DDInter712",
"DDInter864"
] | Famotidine | Histrelin | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
1559,
24,
1616
]
],
[
[
1559,
62,
112
],
[
112,
23,
1616
]
],
[
[
1559,
23,
1247
],
[
1247,
23,
1616
]
],
[
[
1559,
63,
1664
],
[
1664... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Famotidine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and S... |
DB00023 | DB00900 | 305 | 45 | [
"DDInter127",
"DDInter544"
] | Asparaginase Escherichia coli | Didanosine | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Moderate | 1 | [
[
[
305,
24,
45
]
],
[
[
305,
24,
1620
],
[
1620,
23,
45
]
],
[
[
305,
24,
1669
],
[
1669,
62,
45
]
],
[
[
305,
24,
1142
],
[
1142,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Didanosine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a minor interaction that can limit clinical effects when taken with Didanosine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseas... |
DB00468 | DB01229 | 1,424 | 973 | [
"DDInter1557",
"DDInter1377"
] | Quinine | Paclitaxel | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
1424,
24,
973
]
],
[
[
1424,
6,
7524
],
[
7524,
45,
973
]
],
[
[
1424,
21,
28827
],
[
28827,
60,
973
]
],
[
[
1424,
25,
945
],
[
945,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Quinine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Quinine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paclitaxel (Compound)
Quinine (Compound) causes Orthostatic hypotension (Side Effect) and Orthostatic hypotension (Side Effect) is caused by Paclitaxel (Compound)
Quinine may lead to a major life threatening interaction when taken with Sparfloxacin an... |
DB00491 | DB00734 | 127 | 1,664 | [
"DDInter1217",
"DDInter1605"
] | Miglitol | Risperidone | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Moderate | 1 | [
[
[
127,
24,
1664
]
],
[
[
127,
24,
924
],
[
924,
40,
1664
]
],
[
[
127,
21,
28787
],
[
28787,
60,
1664
]
],
[
[
127,
23,
1194
],
[
1194,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Iloperidone and Iloperidone (Compound) resembles Risperidone (Compound)
Miglitol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Risperidone (Compound)
Miglitol may cause a minor interaction tha... |
DB00370 | DB06663 | 1,251 | 1,154 | [
"DDInter1230",
"DDInter1398"
] | Mirtazapine | Pasireotide | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
1251,
25,
1154
]
],
[
[
1251,
63,
1314
],
[
1314,
40,
1154
]
],
[
[
1251,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
1251,
23,
112
],
[
1... | [
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
"Desmo... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin (Compound) resembles Pasireotide (Compound)
Mirtazapine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Mirtazapine may cause a mi... |
DB00330 | DB00444 | 238 | 63 | [
"DDInter689",
"DDInter1765"
] | Ethambutol | Teniposide | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycob... | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Moderate | 1 | [
[
[
238,
24,
63
]
],
[
[
238,
7,
10670
],
[
10670,
46,
63
]
],
[
[
238,
21,
28709
],
[
28709,
60,
63
]
],
[
[
238,
24,
147
],
[
147,
... | [
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
]
],
[
[
"Ethambutol",
"{u} (Compound) upregulates {v} (Gene)",
"KLHL21"
],
[
"KLHL21",
"{u} (Gene) is upregulated by {v} ... | Ethambutol (Compound) upregulates KLHL21 (Gene) and KLHL21 (Gene) is upregulated by Teniposide (Compound)
Ethambutol (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Teniposide (Compound)
Ethambutol may cause a moderate interaction that could exacerbate diseases when ... |
DB06317 | DB09570 | 1,626 | 1,480 | [
"DDInter630",
"DDInter1002"
] | Elotuzumab | Ixazomib | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
1626,
24,
1480
]
],
[
[
1626,
24,
987
],
[
987,
63,
1480
]
],
[
[
1626,
63,
268
],
[
268,
24,
1480
]
],
[
[
1626,
24,
1136
],
[
1136,
... | [
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR s... | Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Elotuzumab may cause a moderate interact... |
DB00186 | DB00295 | 905 | 475 | [
"DDInter1092",
"DDInter1244"
] | Lorazepam | Morphine | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Major | 2 | [
[
[
905,
25,
475
]
],
[
[
905,
6,
16538
],
[
16538,
45,
475
]
],
[
[
905,
21,
28784
],
[
28784,
60,
475
]
],
[
[
905,
24,
820
],
[
820,
... | [
[
[
"Lorazepam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
]
],
[
[
"Lorazepam",
"{u} (Compound) binds {v} (Gene)",
"UGT2B15"
],
[
"UGT2B15",
"{u} (Gene) is bound by {v} (Compound)",
"Morphine"... | Lorazepam (Compound) binds UGT2B15 (Gene) and UGT2B15 (Gene) is bound by Morphine (Compound)
Lorazepam (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Morphine (Compound)
Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Alimemazin... |
DB06754 | DB09420 | 707 | 1,074 | [
"DDInter471",
"DDInter953"
] | Danaparoid | Iodide I-123 | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans. The active constituents are heparan, dermatan and, and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity tha... | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
707,
24,
1074
]
],
[
[
707,
64,
500
],
[
500,
24,
1074
]
],
[
[
707,
24,
1004
],
[
1004,
63,
1074
]
],
[
[
707,
25,
1421
],
[
1421,
... | [
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxapar... | Danaparoid may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phenyl salic... |
DB01197 | DB06792 | 1,603 | 1,606 | [
"DDInter292",
"DDInter1023"
] | Captopril | Lanthanum carbonate | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led... | Moderate | 1 | [
[
[
1603,
24,
1606
]
],
[
[
1603,
40,
610
],
[
610,
24,
1606
]
],
[
[
1603,
63,
1144
],
[
1144,
63,
610
],
[
610,
24,
1606
]
],
[
[
1603,
... | [
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
]
],
[
[
"Captopril",
"{u} (Compound) resembles {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} may cause a mo... | Captopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction tha... |
DB01157 | DB08904 | 304 | 375 | [
"DDInter1875",
"DDInter342"
] | Trimetrexate | Certolizumab pegol | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
304,
25,
375
]
],
[
[
304,
24,
200
],
[
200,
63,
375
]
],
[
[
304,
63,
66
],
[
66,
24,
375
]
],
[
[
304,
24,
1430
],
[
1430,
24,... | [
[
[
"Trimetrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[... | Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00399 | DB00681 | 963 | 1,287 | [
"DDInter1968",
"DDInter85"
] | Zoledronic acid | Amphotericin B | Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid]. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors,... | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Moderate | 1 | [
[
[
963,
24,
1287
]
],
[
[
963,
21,
28841
],
[
28841,
60,
1287
]
],
[
[
963,
24,
663
],
[
663,
24,
1287
]
],
[
[
963,
24,
50
],
[
50,
... | [
[
[
"Zoledronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
]
],
[
[
"Zoledronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Bronchospasm"
],
[
"Bronchospasm",
"{u} (... | Zoledronic acid (Compound) causes Bronchospasm (Side Effect) and Bronchospasm (Side Effect) is caused by Amphotericin B (Compound)
Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases... |
DB00491 | DB00988 | 127 | 817 | [
"DDInter1217",
"DDInter584"
] | Miglitol | Dopamine | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. | Moderate | 1 | [
[
[
127,
24,
817
]
],
[
[
127,
24,
532
],
[
532,
1,
817
]
],
[
[
127,
24,
1148
],
[
1148,
63,
817
]
],
[
[
127,
24,
874
],
[
874,
40... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dobutamine"
],
[
"D... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Dobutamine and Dobutamine (Compound) resembles Dopamine (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could e... |
DB00095 | DB06688 | 66 | 1,430 | [
"DDInter623",
"DDInter1677"
] | Efalizumab | Sipuleucel-T | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
66,
24,
1430
]
],
[
[
66,
24,
175
],
[
175,
24,
1430
]
],
[
[
66,
25,
676
],
[
676,
63,
1430
]
],
[
[
66,
24,
310
],
[
310,
63,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Efalizumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitini... |
DB00095 | DB00290 | 66 | 329 | [
"DDInter623",
"DDInter219"
] | Efalizumab | Bleomycin | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Moderate | 1 | [
[
[
66,
24,
329
]
],
[
[
66,
63,
58
],
[
58,
24,
329
]
],
[
[
66,
24,
372
],
[
372,
63,
329
]
],
[
[
66,
23,
1461
],
[
1461,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bleomycin"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarab... |
DB00344 | DB01191 | 1,302 | 1,039 | [
"DDInter1543",
"DDInter518"
] | Protriptyline | Dexfenfluramine | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Major | 2 | [
[
[
1302,
25,
1039
]
],
[
[
1302,
6,
6112
],
[
6112,
45,
1039
]
],
[
[
1302,
24,
1045
],
[
1045,
63,
1039
]
],
[
[
1302,
25,
868
],
[
868,... | [
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Protriptyline",
"{u} (Compound) binds {v} (Gene)",
"SLC6A4"
],
[
"SLC6A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Protriptyline (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Dexfenfluramine (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib and Dacomitinib may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
... |
DB00758 | DB01175 | 1,347 | 318 | [
"DDInter413",
"DDInter672"
] | Clopidogrel | Escitalopram | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Moderate | 1 | [
[
[
1347,
24,
318
]
],
[
[
1347,
63,
1230
],
[
1230,
1,
318
]
],
[
[
1347,
6,
8374
],
[
8374,
45,
318
]
],
[
[
1347,
18,
11048
],
[
11048,... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
... | Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Clopidogrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Clopidogrel (Compound) downregulates VAT1 (Gene) and VAT1 (G... |
DB00476 | DB01087 | 109 | 1,520 | [
"DDInter608",
"DDInter1520"
] | Duloxetine | Primaquine | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Moderate | 1 | [
[
[
109,
24,
1520
]
],
[
[
109,
24,
1487
],
[
1487,
64,
1520
]
],
[
[
109,
6,
12523
],
[
12523,
45,
1520
]
],
[
[
109,
21,
28722
],
[
2872... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Duloxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Primaquine (Compound)
Duloxetine (Compo... |
DB08885 | DB11866 | 363 | 1,068 | [
"DDInter33",
"DDInter1618"
] | Aflibercept | Romosozumab | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it... | Moderate | 1 | [
[
[
363,
24,
1068
]
],
[
[
363,
24,
384
],
[
384,
63,
1069
],
[
1069,
24,
1068
]
],
[
[
363,
64,
1011
],
[
1011,
64,
1069
],
[
1069,
24,... | [
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romosozumab"
]
],
[
[
"Aflibercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[... | Aflibercept may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Afli... |
DB00851 | DB09061 | 611 | 1,627 | [
"DDInter463",
"DDInter284"
] | Dacarbazine | Cannabidiol | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
611,
24,
1627
]
],
[
[
611,
24,
384
],
[
384,
23,
1627
]
],
[
[
611,
63,
597
],
[
597,
23,
1627
]
],
[
[
611,
24,
1613
],
[
1613,
... | [
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[... | Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and ... |
DB08871 | DB12834 | 36 | 148 | [
"DDInter666",
"DDInter1649"
] | Eribulin | Secnidazole | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive ... | Moderate | 1 | [
[
[
36,
24,
148
]
],
[
[
36,
64,
1593
],
[
1593,
24,
148
]
],
[
[
36,
24,
1480
],
[
1480,
24,
148
]
],
[
[
36,
63,
1191
],
[
1191,
2... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
... | Eribulin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moder... |
DB00795 | DB01249 | 50 | 258 | [
"DDInter1725",
"DDInter958"
] | Sulfasalazine | Iodixanol | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Major | 2 | [
[
[
50,
25,
258
]
],
[
[
50,
25,
497
],
[
497,
1,
258
]
],
[
[
50,
18,
5415
],
[
5415,
46,
258
]
],
[
[
50,
18,
6929
],
[
6929,
57,
... | [
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
],
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} (C... | Sulfasalazine may lead to a major life threatening interaction when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Sulfasalazine (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Iodixanol (Compound)
Sulfasalazine (Compound) downregulates ITGAE (Gene) and ITGAE (Gene) ... |
DB00046 | DB01267 | 1,179 | 519 | [
"DDInter940",
"DDInter1381"
] | Insulin lispro | Paliperidone | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Moderate | 1 | [
[
[
1179,
24,
519
]
],
[
[
1179,
24,
1664
],
[
1664,
1,
519
]
],
[
[
1179,
24,
959
],
[
959,
24,
519
]
],
[
[
1179,
24,
135
],
[
135,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Paliperidone (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction ... |
DB00031 | DB00712 | 20 | 1,274 | [
"DDInter1764",
"DDInter763"
] | Tenecteplase | Flurbiprofen | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Moderate | 1 | [
[
[
20,
24,
1274
]
],
[
[
20,
24,
935
],
[
935,
63,
1274
]
],
[
[
20,
23,
297
],
[
297,
62,
1274
]
],
[
[
20,
24,
529
],
[
529,
24,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove m... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.